

011 0101010101010101
101010101010101010
101010101000101010
0100101011101

Statistical Issues Affecting Biomarker Reliability

Power for a Pipeline

Steven J. Skates PhD
Massachusetts General Hospital and
Harvard Medical School

19 April 2013
Emerging Technologies for 21st Century Clinical Diagnostics: The
45th Annual Oak Ridge Conference

0101010101010101
101010101010101010
0101010101010101

Early Detection of Ovarian Cancer Biomarkers - Power

Perspectives

Possible states of nature

Modeling of pipeline

Review from Statistical Criteria

Power calculations

0100101010101010
101010101010101010
0101010101010101

Early Detection of Ovarian Cancer Biomarkers - Power

Perspective

Quantitative criteria, such as power, provide one source of input into the many criteria for prioritizing candidates for verification

Biology, AIMS, protein biochemistry, etc

Experience as to how to best combine such criteria still being gathered

Early Detection of Ovarian Cancer Biomarkers - Power

Perspective

Statistical modeling of biomarker pipeline is very approximate – first pass approximation

Designed to provide guidance on sample size assuming educated guess at “state of nature”

To answer – “Are we even in the ballpark?”

Early Detection of Ovarian Cancer Biomarkers - Power

Perspective

Why bother?

We have a budget, the budget sets our sample size

What “state of nature” can this sample size detect reliably? (SDs separation, fraction cases producing biomarker)

Early Detection of Ovarian Cancer Biomarkers - Power

Possible states of nature

Bracket by previous experience (e.g. Rx trials)

Separates cases from controls by 1, 2, 3, 4 SDs

Fraction of cases producing biomarker:
10%, 20%, 30%, 50%, 80%

Early Detection of Ovarian Cancer Biomarkers - Power

Possible states of nature

Separates cases from controls by 1, 2, 3, 4 SDs

Fold change if CV between patients = 50%

1 SD = 1.6 fold
 2 SD = 2.7 fold
 3 SD = 4.5 fold
 4 SD = 7.4 fold

4 fold = 2.8 SDs


Early Detection of Ovarian Cancer Biomarkers - Power


Possible states of nature

Separates cases from controls by 1, 2, 3, 4 SDs

Sensitivity at 98% specificity (S98) if all cases produce biomarker, SD cases = 1.5*SD controls

1 SD = 24%
 2 SD = 49%
 3 SD = 74%
 4 SD = 90%





Early Detection of Ovarian Cancer Biomarkers - Power


Possible states of nature

Given state of nature, and verification/clinical assay throughput, how many samples do I need to analyze to reliably detect such a biomarker?

Reach clinical validation stage with 80% probability

Pass through discovery stage with 90% probability &

Pass through verification stage with 90% probability



Early Detection of Ovarian Cancer Biomarkers - Power

Power is derived from increased S/N

Signal increased by increasing:

1. Separation between cases and controls - #SDs
2. Proportion of cases producing biomarker

Noise changed by CV of measurement process

3. Throughput of candidates in verification stage

Statistical Criteria by Stage and Transition for CPTAC Pipeline

An Approach to Determining if a Biomarker is Clinically Useful

1. Define "Intended Use"
2. Define clinical pathway
3. State minimum benefits to harms ratio
 - a) Benefit of true positive
 - b) Benefit of true negative
 - c) Harm of false positive
 - d) Harm of false negative
4. Derive required specificity (ReqSP) assuming 100% sensitivity to achieve acceptable B/H ratio, within clinical pathway
5. Impact of each biomarker is increase in sensitivity at clinically useful specificity (ReqSP)
6. Evaluate sensitivity of biomarker (panel) at ReqSP

Statistical Criteria by Stage and Transition for CPTAC Pipeline

Required Specificity (ReqSP)

Annual incidence of OVCA in postmenopausal women
1 in 2,500

Desired benefit/harm: 1 OVCA in 5 surgeries

500 fold increase

Ultrasound reduces false positives by 10-fold

Require blood test to reduce by 50-fold

Statistical Criteria by Stage and Transition for CPTAC Pipeline

Biomarker Criterion for early detection of OVCA

Required False Positive Rate: 1 in 50 = 2%

Required Specificity (ReqSP): 98%

Sensitivity at 98% Specificity

Statistical Criteria by Stage and Transition for CPTAC Pipeline

Estimate Normal distribution - mean, std deviation for intensity (log) for each protein


Controls = blue = 0, Cases = red = 1

Q98 = 98% quantile for controls = $\text{mean}_0 + 2 \cdot \text{STD}_0$

S98 = Sensitivity at Q98 =
 $\text{Prob Normal} > Z = (\text{Q98} - \text{mean}_1) / \text{STD}_1$

Statistical Criteria by Stage and Transition for CPTAC Pipeline

98% left of cut-point 75% right of cut-point
 $X = \text{avg} + 2 \text{SDs}$ %ile of Normal Dist ($X \mid \text{avg}, \text{SD}$)



Sens = 75% at 98% Spec S98 = 75%

6-fold increase – depends on biological variability
3 standard deviations separates cases from controls

Early Detection of Ovarian Cancer Biomarkers - Power

Reaching Verification

10 cases and 10 controls,
biomarkers expressed in 80% of cases, and separated by 2 SDs

25 cases and 25 controls,
biomarker expressed in 50% of cases, and
separated from controls by 2 SDs,
expressed in 80% of cases, and separated by 1 SD.

50 cases and 50 controls,
biomarker expressed in 20% of cases, chance identified at most 53%
for biomarkers where cases separated by 3 SDs

biomarkers expressed in 10% of cases - unlikely to be detected

Early Detection of Ovarian Cancer Biomarkers - Power

Reaching clinical validation

50 cases and 50 controls
20% of cases producing biomarker, and
2 SDs apart fail to achieve a high probability

250 cases vs. 250 controls
chance < 90% only if cases and controls are 1.0 SDs apart, **and** proportion of cases
producing biomarker is 10% or less

Early Detection of Ovarian Cancer Biomarkers - Power

Conclusions - Power

Statistical modeling produces a first approximation to CPTAC pipeline

Set criteria at each stage based on clinical benefit/harm ratio for intended use

Power of 80% to reach clinical validation stage achieved by attaining 90%
power for discovery and verification stages

Factors affecting sample size

1. Separation between cases & controls
2. Fraction of cases producing biomarker
3. Number of assays for verification, clinical validation to be developed
